Published Date: 02 Mar 2023
A study published online Feb. 27 in JAMA Internal Medicine found that interventions increase prevention but not the association with alcohol use disorder (AUD) in primary care.
Read Full NewsA recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.
The newly approved inhibitor is for patients who previously received another drug of the same class.
1.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
2.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
3.
FDA approves Blenrep for relapsed or refractory multiple myeloma
4.
Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma
5.
New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show
1.
The importance of understanding normal serum osmolality
2.
Innovative Approaches in Oncology for Modern Medicine
3.
Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management
4.
The Future of Hematology: Innovations Every Doctor Should Know
5.
Cutting-Edge Cancer Care: The Precision Revolution in Surgical Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part III
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation